project id: TCGA-PRAD; case submitter id: TCGA-J9-A52D; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wgs: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 1.83; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.62; rna integrity number: 8.7; age at index: 71; days to birth: -26023; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Alive; year of birth: 1941; age at diagnosis: 26023; ajcc clinical m: M0; ajcc clinical t: T2b; ajcc pathologic t: T3a; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 212.0; icd 10 code: C61; last known disease status: not reported; morphology: 8500/3; primary diagnosis: Infiltrating duct carcinoma, NOS; primary gleason grade: Pattern 4; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 5; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2012; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 278; initial weight: 40.0; oct embedded: false; preservation method: Unknown; sample id: d2feded2-c367-4561-91af-9d0c7fc6638f; sample submitter id: TCGA-J9-A52D-01A; portion id: 7439db91-dbea-4770-8adc-40f0bebff2b1; portion submitter id: TCGA-J9-A52D-01A-11; slide id: 2f99d326-e63d-4f4d-8465-c154411fcb09; slide submitter id: TCGA-J9-A52D-01A-01-TS1; percent lymphocyte infiltration: 0.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 0.0; percent stromal cells: 0.0; percent tumor cells: 100.0; percent tumor nuclei: 95.0; section location: TOP;